Azenta (AZTA) said Tuesday Azenta Life Sciences's Genewiz and Form Bio is partnering on developing adeno-associated virus gene therapy via an integrated sequencing and data analysis solution.
The partnership will combine Genewiz's sequencing services for AAV gene therapy with Form Bio's AI-backed analysis pipelines, Azenta said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.